Abstract
Several lines of evidence have shown that the endogenous cannabinoids are implicated in several neuropsychiatric diseases. Notably, preclinical and human clinical studies have shown a pivotal role of the cannabinoid system in nicotine addiction. The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716) was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by nicotine in brain reward area. Rimonabant has been shown to improve the ability of smokers to quit smoking in randomized clinical trials. However, rimonabant was removed from the market due to increased risk of psychiatric side-effects observed in humans. Recently, other components of the endogenous cannabinoid system have been explored. Here, we present the recent advances on the understanding of the role of the different components of the cannabinoid system on nicotine’s effects. Those recent findings suggest possible alternative ways of modulating the cannabinoid system that could have implication for nicotine dependence treatment.
Introduction
Among addictive substances, nicotine use is one of the most prevalent worldwide. The World Health Organization (WHO) estimates that nearly six million tobacco smokers will die every year as a consequence of their tobacco use (1). Therefore, tobacco smoking represents the largest preventable cause of death in the world. Nicotine exerts its effects on the main neurotransmitter systems, such as acetylcholine, dopamine, noradrenaline, serotonin, opioid, glutamate, and gamma-aminobutyric acid (GABA) systems (2–7). There is also mounting evidence supporting the existence of a significant role of the endocannabinoid system in mediating the reinforcing and other addiction-related effects of nicotine. The close overlap of cannabinoid and nicotinic acetylcholine receptors (nAChRs) in certain brain areas such as the midbrain, known to mediate the reinforcing properties of nicotine, but also the hippocampus and the amygdala that are involved in nicotine-associated memory certainly facilitates the interaction between both systems (8–10). There is also evidence of the existence of modulatory interactions between endocannabinoid and cholinergic signaling systems (11–13). Behavioral experiments have shown specific functional interactions between nicotine and the endocannabinoid system that could be mediated by brain structures involved in motivation (14).
The cannabinoid system includes the cannabinoid CB1 and CB2 receptors, endogenous cannabinoids, and the processes responsible for their biosynthesis, cellular uptake, and metabolism (15–18). Endocannabinoids are synthesized on-demand and can activate cannabinoid CB1 and/or CB2 receptors (19, 20). CB1 receptors are believed to be the main mediators of the psychoactive properties of delta-9-tetrahydrocannabinol (THC), which is the main psychoactive component of cannabis (21). CB1 receptors are among the most abundant G-protein-coupled receptors in the central nervous system (CNS) (22). Cannabinoids modify the synaptic efficacy of central neuronal circuits involved in reward and other processes by acting at CB1 receptors located pre-synaptically (23). Although CB2 receptor protein can be detected in the brainstem neurons using western blotting and immunohistochemistry (24), yet, levels of expression of brain CB2 receptors are much lower than those of CB1 receptors (25, 26). CB2 receptor mRNAs were detected in certain regions of the rat brain such as, the cerebellum, cortex, and brainstem using reverse transcription polymerase chain reaction (RT-PCR) (24). In contrast to the predominant pre-synaptic localization of CB1 receptors in the brain, immunoreactivity studies suggest a more likely post-synaptic localization of CB2 receptors (25, 26).
There are several endocannabinoids, of which the most studied have been arachidonoyl ethanolamide (anandamide; AEA) and 2-arachidonoylglycerol (2-AG). Anandamide synthesis is regulated through the conversion of a minor phosphoglyceride, N-arachidonyl phosphatidylethanolamine (N-arachPE), through two possible pathways. The first pathway involves phospholipase D (NAPE-PLD) (27) and the second involves two enzymes, alpha beta hydrolase (ABH4) and glycerophosphodiesterase (GDE1) (28). The exact processes regulating the involvement of these enzymes in the synthesis of anandamide have not been fully elucidated. Cessation of endocannabinoid signaling is hypothesized to happen through the transport inside the cell and the later degradation by specific enzymes. It is further hypothesized that anandamide and 2-AG actually share same the intracellular transport mechanism (17, 23). Anandamide and 2-AG seem to diffuse passively through lipid membranes due their lipophilic nature. Nevertheless, the diffusion process might be facilitated by a selective carrier system (29, 30). After anandamide’s uptake inside the cell, the enzyme fatty acid amide hydrolase (FAAH) degrades it into arachidonic acid and ethanolamine (31, 32). FAAH and CB1 receptors are widely distributed in the CNS and show partial overlap. However, FAAH is mainly available at the post-synaptic neurons whereas CB1 receptors are located at the pre-synaptic neurons (33, 34). On the other hand, 2-AG has its own distinct structure and different biosynthesis and degradation pathways. Moreover, 2-AG appears to be formed under conditions different from those required for the synthesis of anandamide and is modulated by different pharmacological mechanisms. 2-AG is synthesized in response to cellular activation from arachidonic acid-containing membrane phospholipids. The most important pathway for 2-AG synthesis is the phosphatidylinositol (PI)-phospholipase C (PLC)/DAG lipase [diglyceride lipase (DAGL)] pathway, which involves the hydrolysis of inositol phospholipids by PLC. The second pathway for producing 2-AG is through the sequential hydrolysis of PI (35). Although a large number of enzymes are involved in the hydrolysis of monoacyl glycerols, evidence has shown that MAG lipase [monoglyceride lipase (MAGL)] might play a fundamental role on 2-AG degradation. The remaining 2-AG seems to be hydrolyzed by ABHD6 and ABHD12 enzymes (36), although the information on this regard is limited. Interestingly, it has been demonstrated that anandamide enhances the metabolism and in turn attenuates 2-AG effects in the striatum (37). These findings suggest that anandamide and 2-AG might have different actions according to the different physiological or pathophysiological conditions under which they are synthesized (17). Endocannabinoids function as non-conventional neuromodulators whose functions include retrograde signaling and they mediate several types of synaptic plasticity (38). Once released by post-synaptic neurons, endocannabinoids will inhibit neurotransmitter release by pre-synaptic neurons. The respective inhibition of GABA or glutamate release by endocannabinoids mediate depolarization-induced suppression of “inhibition” (DSI) (39, 40) or the depolarization-induced suppression of “excitation” (DSE) (41), respectively. The occurrence of DSE and DSI in the mesocorticolimbic system (42–44) is relevant because of the importance of this system in addiction.
Emerging evidence has shown that the endogenous cannabinoid ligands are implicated in drug addiction processes (10, 45, 46). We will review the literature on nicotine only. Initial preclinical and human clinical studies suggested that the use of CB1 receptor inverse agonists/antagonists such as rimonabant (also known as SR141716) and AM251 might be effective for the treatment of nicotine addiction (47). In fact, rimonabant was able to improve smoking cessation rates in controlled trials (47). However, the use of rimonabant was associated with higher rates of anxiety and depression (48, 49), and consequently this medication was withdrawn from the market in 2008 (50). In this article, we will review the recent advances that have occurred in the last few years regarding our understanding of the different components of the cannabinoid system and how it possibly modulates nicotine addiction.
Nicotine Dependence and Brain Reward Pathways
To better interpret how endocannabinoids modulate the reinforcing effects of nicotine, it is important to understand how nicotine interacts with the different brain reward pathways, particularly the mesolimbic dopaminergic pathway. The psychoactive effects of nicotine are believed to occur through its activation of the nAChRs. These receptors are located in a variety of brain areas and are not limited to the central cholinergic pathways. The nAchRs have been detected in high densities in the thalamus and caudate nucleus, moderate densities in the frontal and temporal parietal cortices, and in the cerebellum with low levels in white matter tracts (51). Exposure to nicotine in a chronic manner leads to desensitization (52) and up regulation (53) of α4β2* subtype of high-affinity nAChRs (54). This receptor subtype has been shown to play a major role in mediating the reinforcing and antinociceptive effects of nicotine. In the ventral tegmental area (VTA), nicotine binds to nAChRs located on nerve terminals of GABAergic and glutamate neurons projecting on the dopaminergic neurons, but also on nAChRs located directly on dopamine neurons (55). The dopamine neurons project to several brain regions implicated in reward including the nucleus accumbens (NAc). Nicotine administration ultimately stimulates the release of dopamine in the dorsal and ventral striatal terminals, notably the NAc (52). These findings have been validated using positron emission tomography (PET) approach (56, 57). Notably, a recent PET study using [11C]-(+)-PHNO PET tracer have shown that tobacco smoking produced elevation of dopamine in the limbic striatum and in extra-striatal area (the ventral pallidum) (57). Interestingly, this study identified that in smokers, dopamine release in the limbic striatum was associated with motivation to smoke, anticipation of pleasure from cigarettes, and relief of withdrawal symptoms. Furthermore, studies have shown that the lesion of the mesolimbic dopamine system (58) or administration of selective dopamine antagonists results in a significant decrease of nicotine self-administration in rats (59). On the other hand, several neurotransmitter systems have shown to play a vital role in nicotine dependence. Studies have shown that nicotine-induced dopamine release can be reduced significantly by atropine (muscarinic receptor antagonist), eticlopride (dopamine D1/2 receptor antagonist), and MK801 [N-methyl-d-aspartate (NMDA) antagonist] (60). It has been shown that smoking cigarettes enhances plasma levels of endogenous opioids (61, 62) and that nicotine stimulates the release of β-endorphins in neuronal cell cultures (63). Furthermore, nicotine-conditioned place preference (CPP) and nicotine-induced antinociception were significantly attenuated in μ-opioid knockout mice compared to wild-type mice (64). Additionally, naloxone has been shown to block nicotine CPP in mice (65).
Endocannabinoid Modulation of Dopaminergic Neuronal Inputs
The dopaminergic system has long been hypothesized to play an essential role in the formulation of goal-directed behaviors of natural rewards and drugs of abuse including nicotine (58, 66, 67). Furthermore, the conditioned-reinforcing properties of drugs of abuse and their associated stimuli are also mediated through the dopaminergic system (68, 69). Dopamine is further involved in the development of behavioral sensitization that follows the repeated administration of drugs of abuse, as well as non-drug stimuli (70).
Several lines of evidence have demonstrated the significance of the dopaminergic system in cue associations. Using a discriminative stimulus and a conditioned stimulus as conditioning tasks associated with a food reward, Miller and colleagues, demonstrated an increase in neuronal firing in the VTA and substantia nigra (71). Similarly, in monkeys, phasic neuronal responses were recorded in response to conditioned stimuli in dopaminergic neurons (72).
The modulatory role of the endocannabinoid system on signaling in the mesolimbic dopamine reward system (73, 74), is believed to be substantiated by its abundant presence within the VTA (75, 76). The ability of endocannabinoids to act as retrograde neurotransmitters (44) allows them to attenuate the activity of external afferents (pre-synaptic neurons) (42) and allows dopamine neurons (post-synaptic neurons) to regulate their own function (43). This topic has been recently reviewed by Wang and Lupica (77) and will be not developed here. It appears that the main endocannabinoid regulating dopamine firing is 2-AG and it has been proposed that the burst firing activity pattern of dopamine neurons as well as the long-term plasticity effects induced by drugs of abuse are regulated by 2-AG (77, 78). The critical role of endocannabinoids mediating the ability of drugs of abuse, including nicotine, to stimulate reward pathway is shown by multiple pharmacological studies (14, 79, 80).
Role of CB1 Receptors on Nicotine Addictive Properties
In rats, the selective CB1 receptor inverse agonist/antagonist rimonabant decreases intravenous nicotine self-administration behavior and also nicotine-induced elevations in extracellular dopamine in the NAc (14). We and others subsequently reported that rimonabant decreases the motivation to self-administer nicotine, as measured using progressive-ratio schedules of reinforcement (81) (see Figure 1), blocks the development of nicotine-induced CPP (82–84), and the reinstatement of previously extinguished nicotine-seeking behavior in rats (81, 85, 86) (see Figure 2). Several studies have shown that genetic deletion of cannabinoid CB1 receptors reduces nicotine-induced CPP (87, 88). Cannabinoid CB1 receptor stimulation, in contrast, increased the motivation to self-administer nicotine as measured using a progressive-ratio schedule of reinforcement (89) (see Figure 3), enhanced cue-induced reinstatement of nicotine-seeking behavior and the discriminative stimulus effects of low doses of nicotine in rats (89) (see Figure 4). Several of these responses in rats were blocked by the CB1 inverse agonist/antagonist rimonabant. However, the CB2 antagonist AM630, was not able to block CB1 stimulation effects, supporting the critical role of CB1 receptors in mediating nicotine-dependent processes (89, 90). Interestingly, blockade of the CB1 receptors in the shell of the NAc, the basolateral amygdala, and the prelimbic cortex (91), but also in the bed nucleus of the stria terminalis (92), is able to reduce nicotine-seeking behavior. Nicotine-taking appears to be controlled by CB1 receptors located in the VTA, but not in the NAc (93). Taken together, these findings indicate that CB1 receptors have a bi-directional role on both nicotine reward/reinforcement and on relapse to nicotine-seeking behavior in abstinent subjects.
Figure 1
Figure 2
Figure 3
Figure 4
CB2 Receptors on Nicotine Addictive Properties
Several lines of evidence indicate that central CB2 receptors could be implicated in modulating several neuropsychiatric disorders, including drug addiction (94–96). In fact, the effects of CB1 and CB2 receptor activation (at high doses) can produce similar effects such as antinociception and catalepsy (97, 98). However, the activation of CB2 receptors by the selective CB2 agonist AM1241 did not have effects on motivation to obtain nicotine or nicotine intake in rats (90). Similarly, the selective CB2 antagonist AM630 did not modify nicotine-taking or motivation to obtain nicotine under the progressive-ratio schedule of reinforcement. Moreover, the CB2 agonist and antagonist were not able to affect cue or nicotine-induced reinstatement of nicotine-seeking behavior (90). Together, these results further support the current literature on the distinct behavioral, neurochemical, and immunological profiles, of CB1 and CB2 receptors. On the other hand, it should be noted that in mice, CB2 receptors have been shown to modulate some addictive properties of drugs of abuse using both genetic and pharmacological models (99, 100). Another recent study by Zhang and colleagues, reported that activation of CB2 receptors in the VTA can attenuate cocaine self-administration in WT and CB1 knockout but not in CB2 knockout mice (101). Moreover, recent studies have documented the relevance of CB2 receptors on the rewarding/reinforcing properties of nicotine in mice (102, 103). Altogether, these results suggest that there may be important species differences that mediate these effects. Further studies performed in non-human primates or human subjects would allow better exploration of these discrepancies.
Role of Endogenous Cannabinoid Ligands in Modulating the Reinforcing Effects of Nicotine
A recent study have shown that the volitional intake of nicotine (i.e., nicotine self-administration in rats) was able to modify anandamide and oleoylethanolamide (OEA) levels in the VTA (104). This is an interesting finding considering that several studies have described the existence of modulatory effects in signaling between the endocannabinoid and cholinergic systems (11–13). The understanding of effects of anandamide and 2-AG in modulating nicotine-reinforcing properties has been facilitated by the discovery of drugs able to interfere with the different processes involved in the synthesis, reuptake, and inactivation of these endocannabinoids. Among those drugs, N-(4-hydroxyphenyl)-arachidonamide (AM404) and cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) produce elevation of anandamide levels by blocking anandamide reuptake or by inhibiting FAAH, respectively (105, 106).
Based on observations of the effects of cannabinoid receptor agonists and antagonists on nicotine’s rewarding properties, one could speculate that increasing brain anandamide levels might enhance nicotine’s rewarding/reinforcing effects. Consistent with this prediction, Merritt et al. (88) observed enhanced nicotine CPP in FAAH knockout mice. Similarly, the pre-treatment with URB597 enhanced nicotine CPP in mice (88). Administration of a sub-threshold dose of nicotine that did not produce CPP in wild-type mice effectively produced CPP in FAAH knockout mice, and this effect was mediated by CB1 receptors (88). The enhancement of nicotine’s rewarding effects in FAAH knockout mice further supports previous studies where co-administration of sub-threshold doses of nicotine and THC produced nicotine CPP in mice (107). On the other hand, no differences on nicotine CPP were observed between FAAH knockout and wild-type mice when higher doses of nicotine were tested (88).
In a marked contrast to the results of Merritt et al. (88) in mice, FAAH inhibition by URB597 has been shown to reverse some addiction-related behavioral and neurochemical effects of nicotine in rats (81, 108). The inhibition of FAAH by URB597 was able to prevent the development of nicotine-induced CPP, reduced acquisition of nicotine self-administration behavior, and inhibited reinstatement of nicotine-seeking behavior induced by nicotine priming and cue-induced reinstatement in abstinent rats, while demonstrating no rewarding effects per se (108). However, there was no impact on nicotine-taking assessed using a fixed-ratio or a progressive-ratio schedule of reinforcement (81). A possible explanation for the differences observed between those studies is the fact that different species were used in these studies: rats (81, 108) vs. mice (88). However, URB597-induced increases in anandamide brain levels do not differ between mice and rats (109).
Possible Involvement of Non-Cannabinoid Systems FAAH Inhibitors Effects
There is a surprising similarity between the effects of FAAH inhibition by URB597, which is expected to enhance anandamide levels and, thus, enhance cannabinoid CB1 receptor signaling, and those of rimonabant, described earlier, which blocks cannabinoid CB1 receptor signaling. In addition to a similarity in behavioral effects, it has been shown that both compounds, URB597 and rimonabant, were able to block nicotine-induced increases of dopamine levels in the NAc (14, 108). The similar effects of URB597 and rimonabant described above could be explained by the involvement of non-cannabinoid peroxisome proliferator-activated nuclear receptor (PPAR-α) systems (110, 111). Therefore, PPAR-α receptors seems to mediate the effects of FAAH inhibition on nicotine’s abuse-related behavioral and neurochemical effects in both rats and monkeys while CB1 receptors may play the major role in mediating the effects of FAAH inhibition on nicotine’s abuse-related behavioral and neurochemical effects in mice. This is supported by findings by Fegley et al. (109), showing that 2 h after treatment with 0.3 mg/kg URB597, there was only a twofold increase in brain levels of the endogenous PPAR-α ligand OEA and palmitoylethanolamide (PEA) in mice compared to a four to fivefold increase in OEA and PEA levels in rats (109). In contrast, as commented above, URB597-induced increases in anandamide brain levels do not differ between mice and rats (109). Moreover, the PPAR-α receptor antagonist MK-886 blocked URB597-induced reductions in nicotine’s effects on dopaminergic neuronal activity in rats (112). Similar to URB597, a variety of natural and synthetic PPAR-α receptor agonists were shown to decrease nicotine-reinforcing properties and reinstatement nicotine-seeking in different species (111). Another mechanism by which PPAR-α ligands are proposed to modulate the reinforcing effects of nicotine is downstream that activation of α7-nAChR subtype. During low activity, acetylcholine preferentially binds to high-affinity β2-nAChRs. This binding does not trigger nAChRs-mediated modulation of PPAR-α ligands. However, upon activation of cholinergic receptors, low affinity α7-nAChRs located in the extra dendritic regions of dopaminergic neurons are activated. This activation leads to an increase in intracellular Ca2+ which stimulates the synthesis of the PPAR-α ligands OEA and PEA as well as, anandamide. These ligands in turn activate PPAR-α which exerts negative modulation of β2-nAChRs through tyrosine kinase-mediated phosphorylation of β2-nAChRs. This mechanism demonstrates how dopaminergic neurons in the VTA have an ability to self-regulate their firing through selectively increasing OEA and PEA levels (110, 113). Thus, PPAR-α receptors could also be mediating their inhibitory effect on nicotine’s addiction-related behavioral and neurochemical effects through a non-FAAH pathway (111).
Anandamide might also modulate nicotine effects by targeting other receptors such as transient potential receptor of vanilloid type 1 (TRPV1) or even nicotine receptors. Indeed, anandamide has been shown to inhibit α4β2-nAChRs function in a CB1 receptor-independent manner (114, 115). Therefore, the effect of endocannabinoids on nicotine-reinforcing properties seems to be complex and suitable of being affected by different variables including the species and nicotine doses being tested. Other non-cannabinoid systems as vanilloid and PPAR-α might also be involved.
Similarities between FAAH Inhibitors and Endocannabinoid Uptake Inhibitors Effects
In support of the results obtained with the FAAH inhibitor URB 597, the anandamide uptake inhibitor VDM11 (5Z, 8Z, 11Z, 14Z)-N-(4-hydroxy-2-methylphenyl)-5, 8, 11, 14-eicosatetraenamide, was able to reduce both cue- and nicotine-induced reinstatement of nicotine-seeking behavior. However, VDM11 did not affect responding for nicotine under fixed-ratio or progressive-ratio schedules of reinforcement (116) (see Figure 5). Findings with VDM11 were further confirmed using AM404, another anandamide uptake inhibitor, which also attenuated cue and nicotine priming reinstatement of nicotine-seeking behavior (117). Additionally, AM404 decreased nicotine CPP and its reinstatement. AM404 has been also shown to attenuate dopamine increase on the NAc shell following nicotine injection (118). The fact that two different ligands developed to elevate anandamide levels produce similar effects, strongly suggest that those effects are mediated by anandamide elevation.
Figure 5
The effects observed with VDM11 and AM404 on nicotine reward/reinforcement, were further supported by Oleson and Cheer (119) using the intracranial brain stimulation paradigm. Elevating levels of anandamide using the anandamide uptake inhibitor VDM11 reduced NAc neural encoding of reward-predictive cues and attenuated reward seeking, defined as the time occurring between cue presentation and a reward-directed behavioral response (120). A possible explanation for these findings is that VDM11 increases anandamide to a greater extent than 2-AG in vivo (121). Since anandamide functions as a partial agonist, the elevation of its levels in the brain induced by VDM11 might allow it to compete with 2-AG, a full CB1 receptor agonist (122), thereby anandamide might block 2-AG effects on reward seeking. In fact, comparing different behavioral studies suggest that anandamide and 2-AG may have opposite effects on reward-seeking behavior (81, 116, 119, 120). Interestingly, anandamide and 2-AG are effective reinforcers as evaluated using the intravenous drug self-administration paradigm in squirrel monkeys (123, 124). However, while 2-AG increases dopamine neurotransmission (125) and facilitates reward-directed behavior (125, 126), the elevation of anandamide levels attenuates the ability of cues to motivate reward-seeking behavior (81, 116, 119, 120).
It has been suggested that VDM11 might be actually a substrate for FAAH. Thus, it has been shown that VDM11 reduces FAAH hydrolysis of anandamide in vitro [(127, 128), also see Ref. (129)]. Therefore, the above described effects of VDM11 attenuating reward seeking might be due FAAH inhibition as well as reduced anandamide uptake. In that case, other fatty acid amides affected by FAAH catabolic effects, such as PEA and OEA, might also potentiate the effects of anandamide at TRPV1 receptors (130). As the specific pharmacological mechanisms of action of endocannabinoids remain unclear, it would be interesting to investigate the brain regions involved in mediating the effects observed with increasing levels of anandamide (e.g., intraregional injection of anandamide uptake inhibitors in areas of the brain that may be involved in mediating reward/reinforcement such as the basolateral amygdala and the NAc shell) (131). The ubiquitous nature of the endocannabinoid system might provide another interpretation regarding the pharmacological mechanism of action by which anandamide uptake inhibitors modulate neural mechanisms of reward seeking (132–134).
An alternative explanation of how VDM11 might attenuate reward seeking comes from the pharmacological inhibition of the membrane transporter. The bi-directional role of the membrane transporter in transporting anandamide and 2-AG (29, 30, 135) might explain the effects of VDM11 in reward seeking. In fact, recent studies using VDM11 have reported effects that are in close resemblance to those observed following CB1 receptor blockade (116, 119).
Endocannabinoids and Nicotine Withdrawal
Endocannabinoids seem to be implicated in the response to withdrawal from nicotine. The concomitant treatment with nicotine and THC in mice induced an increased withdrawal syndrome when these mice were challenged with rimonabant (107). Additionally, the administration of THC seems to attenuate the magnitude of nicotine withdrawal (136). On the other hand, rimonabant failed to induce withdrawal in nicotine-dependent animals (136), suggesting that the cannabinoid system is not involved in the expression of nicotine physical dependence. However, more recent findings have reported modification in the number of nicotine receptors following chronic exposure to cannabinoids (137). Additionally, Cippitteli and colleagues reported that withdrawal from nicotine is associated with fluctuations in anandamide but not in 2-AG (138). Interestingly, the same study showed that administration of URB597, decreased nicotine withdrawal associated anxiety, but did not alter somatic signs of nicotine withdrawal (138).
Conclusion
It appears, from the experiments conducted in preclinical models (and partly validated by the testing of rimonabant in human clinical trials) that the CB1 receptors are critically involved in mediating nicotine reward/reinforcement. CB1 receptors also seem to be involved in mediating cue and nicotine priming reinstatement of nicotine-seeking behavior. Further work is needed to explore the role of CB1 receptors in nicotine-seeking induced by stress. It appears that many of these findings hold true in non-human primate studies as well as rodents (46, 47, 139). Thus, the CB1 receptor appears to be a logical target for drug development. As inverse agonist/antagonists have been found to have negative side-effects in humans (i.e., anxiety/depression), novel approaches, such as neutral CB1 receptor antagonists that might be effective against drug addiction without inverse agonist/antagonists side-effects, could represent a better therapeutic option (140–142). Limited experiments conducted in rats, suggest that the CB2 receptor has no involvement in mediating nicotine self-administration and relapse to nicotine-seeking. However, since differences have been reported in the role of CB2 receptors in mice and rats, it would be interesting to further explore the role of CB2 receptors before concluding that this receptor is not an interesting target. Recent experiments suggest that elevating brain anandamide levels would be an effective strategy to reduce relapse to nicotine-seeking behavior, but not to reduce ongoing nicotine-taking behavior. This is of great interest as such a strategy has been shown to decrease anxiety and depression in some animal models and may therefore be better tolerated than CB1 receptor inverse agonist/antagonists. However, we have no validation in humans of these interesting findings. Finally, exploring the role of the endogenous cannabinoid receptor ligand 2-AG on nicotine-taking and -seeking behavior will improve our understanding of the respective behavioral role of different endocannabinoids. Overall, those recent studies suggest that the endocannabinoid system still presents many opportunities for development of novel therapeutic strategies for nicotine addiction.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
WHO. WHO Report on the Global Tobacco Epidemic 2013. (2013).
2
WilkieGIHutsonPHStephensMWWhitingPWonnacottS. Hippocampal nicotinic autoreceptors modulate acetylcholine release. Biochem Soc Trans (1993) 21:429–31.
3
ClarkePBReubenM. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. Br J Pharmacol (1996) 117:595–606.10.1111/j.1476-5381.1996.tb15232.x
4
PontieriFETandaGOrziFDi ChiaraG. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature (1996) 382:255–7.10.1038/382255a0
5
YangXCriswellHEBreeseGR. Nicotine-induced inhibition in medial septum involves activation of presynaptic nicotinic cholinergic receptors on gamma-aminobutyric acid-containing neurons. J Pharmacol Exp Ther (1996) 276:482–9.
6
KennyPJFileSENealMJ. Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem (2000) 75:2409–14.10.1046/j.1471-4159.2000.0752409.x
7
BerrenderoFRobledoPTrigoJMMartin-GarciaEMaldonadoR. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev (2010) 35:220–31.10.1016/j.neubiorev.2010.02.006
8
PicciottoMRCaldaroneBJKingSLZachariouV. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology (2000) 22:451–65.10.1016/S0893-133X(99)00146-3
9
SchlickerEKathmannM. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci (2001) 22:565–72.10.1016/S0165-6147(00)01805-8
10
Le FollBGoldbergSR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther (2005) 312:875–83.10.1124/jpet.104.077974
11
NarushimaMUchigashimaMFukayaMMatsuiMManabeTHashimotoKet alTonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. J Neurosci (2007) 27:496–506.10.1523/JNEUROSCI.4644-06.2007
12
AdermarkL. Modulation of endocannabinoid-mediated long-lasting disinhibition of striatal output by cholinergic interneurons. Neuropharmacology (2011) 61:1314–20.10.1016/j.neuropharm.2011.07.039
13
OldenburgIADingJB. Cholinergic modulation of synaptic integration and dendritic excitability in the striatum. Curr Opin Neurobiol (2011) 21:425–32.10.1016/j.conb.2011.04.004
14
CohenCPerraultGVoltzCSteinbergRSoubrieP. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol (2002) 13:451–63.10.1097/00008877-200209000-00018
15
Di MarzoVDe PetrocellisLBisognoT. Endocannabinoids Part I: molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors. Expert Opin Ther Targets (2001) 5:241–65.10.1517/14728222.5.2.241
16
SugiuraTWakuK. Cannabinoid receptors and their endogenous ligands. J Biochem (2002) 132:7–12.10.1093/oxfordjournals.jbchem.a003200
17
PiomelliD. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 4:873–84.10.1038/nrn1247
18
Di MarzoV. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci (2006) 27:134–40.10.1016/j.tips.2006.01.010
19
PertweeRG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther (1997) 74:129–80.10.1016/S0163-7258(97)82001-3
20
Di MarzoVMelckDBisognoTDe PetrocellisL. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci (1998) 21:521–8.10.1016/S0166-2236(98)01283-1
21
MechoulamRParkerLA. The endocannabinoid system and the brain. Annu Rev Psychol (2013) 64:21–47.10.1146/annurev-psych-113011-143739
22
HerkenhamMLynnABLittleMDJohnsonMRMelvinLSDe CostaBRet alCannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 87:1932–6.10.1073/pnas.87.5.1932
23
FreundTFKatonaIPiomelliD. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 83:1017–66.10.1152/physrev.00004.2003
24
Van SickleMDDuncanMKingsleyPJMouihateAUrbaniPMackieKet alIdentification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 310:329–32.10.1126/science.1115740
25
GongJPOnaiviESIshiguroHLiuQRTagliaferroPABruscoAet alCannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 1071:10–23.10.1016/j.brainres.2005.11.035
26
OnaiviESIshiguroHGongJPPatelSPerchukAMeozziPAet alDiscovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci (2006) 1074:514–36.10.1196/annals.1369.052
27
OkamotoYTsuboiKUedaN. Enzymatic formation of anandamide. Vitam Horm (2009) 81:1–24.10.1016/S0083-6729(09)81001-7
28
SimonGMCravattBF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem (2008) 283:9341–9.10.1074/jbc.M707807200
29
LigrestiAMoreraEVan Der SteltMMonoryKLutzBOrtarGet alFurther evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J (2004) 380:265–72.10.1042/BJ20031812
30
RonesiJGerdemanGLLovingerDM. Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci (2004) 24:1673–9.10.1523/JNEUROSCI.5214-03.2004
31
DesarnaudFCadasHPiomelliD. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem (1995) 270:6030–5.10.1074/jbc.270.11.6030
32
HillardCJEdgemondWSCampbellWB. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J Neurochem (1995) 64:677–83.10.1046/j.1471-4159.1995.64020677.x
33
TsouKNogueronMIMuthianSSanudo-PenaMCHillardCJDeutschDGet alFatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett (1998) 254:137–40.10.1016/S0304-3940(98)00700-9
34
EgertovaMCravattBFElphickMR. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience (2003) 119:481–96.10.1016/S0306-4522(03)00145-3
35
UedaHKobayashiTKishimotoMTsutsumiTOkuyamaH. A possible pathway of phosphoinositide metabolism through EDTA-insensitive phospholipase A1 followed by lysophosphoinositide-specific phospholipase C in rat brain. J Neurochem (1993) 61:1874–81.10.1111/j.1471-4159.1993.tb09829.x
36
BlankmanJLSimonGMCravattBF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol (2007) 14:1347–56.10.1016/j.chembiol.2007.11.006
37
MaccarroneMRossiSBariMDe ChiaraVFezzaFMusellaAet alAnandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci (2008) 11:152–9.10.1038/nn2042
38
KanoMOhno-ShosakuTHashimotodaniYUchigashimaMWatanabeM. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev (2009) 89:309–80.10.1152/physrev.00019.2008
39
Ohno-ShosakuTMaejimaTKanoM. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron (2001) 29:729–38.10.1016/S0896-6273(01)00247-1
40
WilsonRINicollRA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410:588–92.10.1038/35069076
41
KreitzerACRegehrWG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 29:717–27.10.1016/S0896-6273(01)00246-X
42
KatonaIRanczEAAcsadyLLedentCMackieKHajosNet alDistribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci (2001) 21:9506–18.
43
RobbeDAlonsoGDuchampFBockaertJManzoniOJ. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci (2001) 21:109–16.
44
MelisMPistisMPerraSMuntoniALPillollaGGessaGL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci (2004) 24:53–62.10.1523/JNEUROSCI.4503-03.2004
45
De VriesTJShahamYHombergJRCrombagHSchuurmanKDiebenJet alA cannabinoid mechanism in relapse to cocaine seeking. Nat Med (2001) 7:1151–4.10.1038/nm1001-1151
46
MaldonadoRValverdeOBerrenderoF. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci (2006) 29:225–32.10.1016/j.tins.2006.01.008
47
Le FollBForgetBAubinHJGoldbergSR. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol (2008) 13:239–52.10.1111/j.1369-1600.2008.00113.x
48
MoreiraFAGriebMLutzB. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab (2009) 23:133–44.10.1016/j.beem.2008.09.003
49
NathanPJO’neillBVNapolitanoABullmoreET. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther (2011) 17:490–505.10.1111/j.1755-5949.2010.00172.x
50
Le FollBGorelickDAGoldbergSR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 205:171–4.10.1007/s00213-009-1506-7
51
PatersonDNordbergA. Neuronal nicotinic receptors in the human brain. Prog Neurobiol (2000) 61:75–111.10.1016/S0301-0082(99)00045-3
52
PidoplichkoVIDebiasiMWilliamsJTDaniJA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature (1997) 390:401–4.10.1038/37120
53
FloresCMRogersSWPabrezaLAWolfeBBKellarKJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol (1992) 41:31–7.
54
WhitingPJLiuRMorleyBJLindstromJM. Structurally different neuronal nicotinic acetylcholine receptor subtypes purified and characterized using monoclonal antibodies. J Neurosci (1987) 7:4005–16.
55
BalfourDJ. The role of mesoaccumbens dopamine in nicotine dependence. Curr Top Behav Neurosci (2015) 24:55–98.10.1007/978-3-319-13482-6_3
56
BrodyALOlmsteadRELondonEDFarahiJMeyerJHGrossmanPet alSmoking-induced ventral striatum dopamine release. Am J Psychiatry (2004) 161:1211–8.10.1176/appi.ajp.161.7.1211
57
Le FollBGurandaMWilsonAAHouleSRusjanPMWingVCet alElevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans. Neuropsychopharmacology (2014) 39:415–24.10.1038/npp.2013.209
58
CorrigallWAFranklinKBCoenKMClarkePB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) (1992) 107:285–9.10.1007/BF02245149
59
CorrigallWACoenKM. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) (1991) 104:171–6.10.1007/BF02244174
60
SzirakiISershenHHashimALajthaA. Receptors in the ventral tegmental area mediating nicotine-induced dopamine release in the nucleus accumbens. Neurochem Res (2002) 27:253–61.10.1023/A:1014844823534
61
PomerleauOFFertigJBSeylerLEJaffeJ. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology (Berl) (1983) 81:61–7.10.1007/BF00439275
62
del ArbolJLMunozJROjedaLCascalesALIrlesJRMirandaMTet alPlasma concentrations of beta-endorphin in smokers who consume different numbers of cigarettes per day. Pharmacol Biochem Behav (2000) 67:25–8.10.1016/S0091-3057(00)00291-4
63
BoyadjievaNISarkarDK. Role of microglia in ethanol’s apoptotic action on hypothalamic neuronal cells in primary cultures. Alcohol Clin Exp Res (2010) 34:1835–42.10.1111/j.1530-0277.2010.01271.x
64
BerrenderoFKiefferBLMaldonadoR. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci (2002) 22:10935–40.
65
WaltersCLCleckJNKuoYCBlendyJA. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron (2005) 46:933–43.10.1016/j.neuron.2005.05.005
66
CarboniEImperatoAPerezzaniLDi ChiaraG. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience (1989) 28:653–61.10.1016/0306-4522(89)90012-2
67
Di CianoPEverittBJ. The GABA(B) receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats. Neuropsychopharmacology (2003) 28:510–8.10.1038/sj.npp.1300088
68
SchultzWTremblayLHollermanJR. Reward prediction in primate basal ganglia and frontal cortex. Neuropharmacology (1998) 37:421–9.10.1016/S0028-3908(98)00071-9
69
StuberGDKlankerMDe RidderBBowersMSJoostenRNFeenstraMGet alReward-predictive cues enhance excitatory synaptic strength onto midbrain dopamine neurons. Science (2008) 321:1690–2.10.1126/science.1160873
70
BourdelaisAKalivasPW. High sensitivity HPLC assay for GABA in brain dialysis studies. J Neurosci Methods (1991) 39:115–21.10.1016/0165-0270(91)90077-D
71
MillerJDSangheraMKGermanDC. Mesencephalic dopaminergic unit activity in the behaviorally conditioned rat. Life Sci (1981) 29:1255–63.10.1016/0024-3205(81)90231-9
72
SchultzWApicellaPLjungbergT. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J Neurosci (1993) 13:900–13.
73
Fernandez-RuizJHernandezMRamosJA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther (2010) 16:e72–91.10.1111/j.1755-5949.2010.00144.x
74
MelisMMuntoniALPistisM. Endocannabinoids and the processing of value-related signals. Front Pharmacol (2012) 3:7.10.3389/fphar.2012.00007
75
MatyasFUrbanGMWatanabeMMackieKZimmerAFreundTFet alIdentification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology (2008) 54:95–107.10.1016/j.neuropharm.2007.05.028
76
BuczynskiMWParsonsLH. Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol (2010) 160:423–42.10.1111/j.1476-5381.2010.00787.x
77
WangHLupicaCR. Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes. Prog Neuropsychopharmacol Biol Psychiatry (2014) 52:24–7.10.1016/j.pnpbp.2014.01.019
78
MelisMPerraSMuntoniALPillollaGLutzBMarsicanoGet alPrefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci (2004) 24:10707–15.10.1523/JNEUROSCI.3502-04.2004
79
CheerJFWassumKMSombersLAHeienMLAriansenJLAragonaBJet alPhasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci (2007) 27:791–5.10.1523/JNEUROSCI.4152-06.2007
80
GriederTEGeorgeOTanHGeorgeSRLe FollBLavioletteSRet alPhasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. Proc Natl Acad Sci U S A (2012) 109:3101–6.10.1073/pnas.1114422109
81
ForgetBCoenKMLe FollB. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration – comparison with CB(1) receptor blockade. Psychopharmacology (Berl) (2009) 205:613–24.10.1007/s00213-009-1569-5
82
Le FollBGoldbergSR. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport (2004) 15:2139–43.10.1097/00001756-200409150-00028
83
ForgetBHamonMThiebotMH. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) (2005) 181:722–34.10.1007/s00213-005-0015-6
84
HashemizadehSSardariMRezayofA. Basolateral amygdala CB1 cannabinoid receptors mediate nicotine-induced place preference. Prog Neuropsychopharmacol Biol Psychiatry (2014) 51:65–71.10.1016/j.pnpbp.2014.01.010
85
CohenCPerraultGGriebelGSoubrieP. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB(1)) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology (2005) 30:145–55.10.1038/sj.npp.1300541
86
DiergaardeLDe VriesWRaasoHSchoffelmeerANDe VriesTJ. Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist rimonabant (SR141716A). Neuropharmacology (2008) 55:712–6.10.1016/j.neuropharm.2008.06.003
87
CastaneAValjentELedentCParmentierMMaldonadoRValverdeO. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology (2002) 43:857–67.10.1016/S0028-3908(02)00118-1
88
MerrittLLMartinBRWaltersCLichtmanAHDamajMI. The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther (2008) 326:483–92.10.1124/jpet.108.138321
89
GamaleddinIWertheimCZhuAZCoenKMVemuriKMakryannisAet alCannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol (2012) 17:47–61.10.1111/j.1369-1600.2011.00314.x
90
GamaleddinIZvonokAMakriyannisAGoldbergSRLe FollB. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 7:e29900.10.1371/journal.pone.0029900
91
KodasECohenCLouisCGriebelG. Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology (Berl) (2007) 194:161–71.10.1007/s00213-007-0813-0
92
ReisigerARKauflingJManzoniOCadorMGeorgesFCailleS. Nicotine self-administration induces CB1-dependent LTP in the bed nucleus of the stria terminalis. J Neurosci (2014) 34:4285–92.10.1523/JNEUROSCI.3149-13.2014
93
SimonnetACadorMCailleS. Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. Addict Biol (2013) 18:930–6.10.1111/j.1369-1600.2012.00476.x
94
IshiguroHIwasakiSTeasenfitzLHiguchiSHoriuchiYSaitoTet alInvolvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J (2007) 7:380–5.10.1038/sj.tpj.6500431
95
OnaiviESIshiguroHGongJPPatelSMeozziPAMyersLet alBrain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 3:e1640.10.1371/journal.pone.0001640
96
IshiguroHHoriuchiYIshikawaMKogaMImaiKSuzukiYet alBrain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry (2010) 67:974–82.10.1016/j.biopsych.2009.09.024
97
ValenzanoKJTafesseLLeeGHarrisonJEBouletJMGottshallSLet alPharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology (2005) 48:658–72.10.1016/j.neuropharm.2004.12.008
98
RahnEJMakriyannisAHohmannAG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 152:765–77.10.1038/sj.bjp.0707333
99
XiZXPengXQLiXSongRZhangHYLiuQRet alBrain cannabinoid CB(2) receptors modulate cocaine’s actions in mice. Nat Neurosci (2011) 14:1160–6.10.1038/nn.2874
100
Aracil-FernandezATrigoJMGarcia-GutierrezMSOrtega-AlvaroATernianovANavarroDet alDecreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB(2) receptors. Neuropsychopharmacology (2012) 37:1749–63.10.1038/npp.2012.22
101
ZhangHYGaoMLiuQRBiGHLiXYangHJet alCannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A (2014) 111:E5007–15.10.1073/pnas.1413210111
102
Ignatowska-JankowskaBMMuldoonPPLichtmanAHDamajMI. The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. Psychopharmacology (Berl) (2013) 229:591–601.10.1007/s00213-013-3117-6
103
NavarreteFRodriguez-AriasMMartin-GarciaENavarroDGarcia-GutierrezMSAguilarMAet alRole of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology (2013) 38:2515–24.10.1038/npp.2013.157
104
BuczynskiMWPolisIYParsonsLH. The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. Neuropsychopharmacology (2013) 38:574–84.10.1038/npp.2012.210
105
BeltramoMStellaNCalignanoALinSYMakriyannisAPiomelliD. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 277:1094–7.10.1126/science.277.5329.1094
106
KathuriaSGaetaniSFegleyDValinoFDurantiATontiniAet alModulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2003) 9:76–81.10.1038/nm803
107
ValjentEMitchellJMBessonMJCabocheJMaldonadoR. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol (2002) 135:564–78.10.1038/sj.bjp.0704479
108
SchermaMPanlilioLVFaddaPFattoreLGamaleddinILe FollBet alInhibition of anandamide hydrolysis by URB597 reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther (2008) 327:482–90.10.1124/jpet.108.142224
109
FegleyDGaetaniSDurantiATontiniAMorMTarziaGet alCharacterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3’-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2005) 313:352–8.10.1124/jpet.104.078980
110
MelisMCartaSFattoreLToluSYasarSGoldbergSRet alPeroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors. Biol Psychiatry (2010) 68:256–64.10.1016/j.biopsych.2010.04.016
111
MasciaPPistisMJustinovaZPanlilioLVLuchicchiALeccaSet alBlockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry (2011) 69:633–41.10.1016/j.biopsych.2010.07.009
112
LuchicchiALeccaSCartaSPillollaGMuntoniALYasarSet alEffects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors. Addict Biol (2010) 15:277–88.10.1111/j.1369-1600.2010.00222.x
113
MelisMCartaGPistisMBanniS. Physiological role of peroxisome proliferator-activated receptors type alpha on dopamine systems. CNS Neurol Disord Drug Targets (2013) 12:70–7.10.2174/1871527311312010012
114
SpivakCELupicaCROzM. The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol (2007) 72:1024–32.10.1124/mol.107.036939
115
ButtCAlptekinAShippenbergTOzM. Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem (2008) 105:1235–43.10.1111/j.1471-4159.2008.05225.x
116
GamaleddinIGurandaMGoldbergSRLe FollB. The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. Br J Pharmacol (2011) 164:1652–60.10.1111/j.1476-5381.2011.01440.x
117
GamaleddinIGurandaMSchermaMFrattaWMakriyannisAVadivelSKet alAM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. J Psychopharmacol (2013) 27:564–71.10.1177/0269881113477710
118
SchermaMJustinovaZZanettiniCPanlilioLVMasciaPFaddaPet alThe anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol (2012) 165:2539–48.10.1111/j.1476-5381.2011.01467.x
119
OlesonEBCheerJF. Paradoxical effects of the endocannabinoid uptake inhibitor VDM11 on accumbal neural encoding of reward predictive cues. Synapse (2012) 66:984–8.10.1002/syn.21587
120
OlesonEBCheerJF. A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb Perspect Med (2012) 2:a012229.10.1101/cshperspect.a012229
121
van der SteltMMazzolaCEspositoGMatiasIPetrosinoSDe FilippisDet alEndocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci (2006) 63:1410–24.10.1007/s00018-006-6037-3
122
SavinainenJRJarvinenTLaineKLaitinenJT. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol (2001) 134:664–72.10.1038/sj.bjp.0704297
123
JustinovaZSolinasMTandaGRedhiGHGoldbergSR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci (2005) 25:5645–50.10.1523/JNEUROSCI.0951-05.2005
124
JustinovaZYasarSRedhiGHGoldbergSR. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. J Neurosci (2011) 31:7043–8.10.1523/JNEUROSCI.6058-10.2011
125
OlesonEBBeckertMVMorraJTLansinkCSCachopeRAbdullahRAet alEndocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron (2012) 73:360–73.10.1016/j.neuron.2011.11.018
126
Gutierrez-LopezMDLlopisNFengSBarrettDAO’sheaEColadoMI. Involvement of 2-arachidonoyl glycerol in the increased consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine. Br J Pharmacol (2010) 160:772–83.10.1111/j.1476-5381.2010.00720.x
127
VandevoordeSFowlerCJ. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol (2005) 145:885–93.10.1038/sj.bjp.0706253
128
HillardCJShiLTunikiVRFalckJRCampbellWB. Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci (2007) 33:18–24.10.1007/s12031-007-0045-0
129
FegleyDKathuriaSMercierRLiCGoutopoulosAMakriyannisAet alAnandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 101:8756–61.10.1073/pnas.0400997101
130
Di MarzoV. Anandamide serves two masters in the brain. Nat Neurosci (2010) 13:1446–8.10.1038/nn1210-1446
131
Soria-GomezEMatiasIRueda-OrozcoPECisnerosMPetrosinoSNavarroLet alPharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol (2007) 151:1109–16.10.1038/sj.bjp.0707313
132
BisognoTMaccarroneMDe PetrocellisLJarrahianAFinazzi-AgroAHillardCet alThe uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem (2001) 268:1982–9.10.1046/j.1432-1327.2001.02072.x
133
HajosNKathuriaSDinhTPiomelliDFreundTF. Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur J Neurosci (2004) 19:2991–6.10.1111/j.0953-816X.2004.03433.x
134
DiSBoudabaCPopescuIRWengFJHarrisCMarcheselliVLet alActivity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J Physiol (2005) 569:751–60.10.1113/jphysiol.2005.097477
135
ChiccaAMarazziJNicolussiSGertschJ. Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem (2012) 287:34660–82.10.1074/jbc.M112.373241
136
BalerioGNAsoEBerrenderoFMurtraPMaldonadoR. Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci (2004) 20:2737–48.10.1111/j.1460-9568.2004.03714.x
137
MateosBBorcelELorigaRLuesuWBiniVLlorenteRet alAdolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB(1) cannabinoid receptors. J Psychopharmacol (2011) 25:1676–90.10.1177/0269881110370503
138
CippitelliAAstaritaGDurantiACaprioliGUbaldiMStopponiSet alEndocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS One (2011) 6:e28142.10.1371/journal.pone.0028142
139
SchermaMFaddaPLe FollBForgetBFrattaWGoldbergSRet alThe endocannabinoid system: a new molecular target for the treatment of tobacco addiction. CNS Neurol Disord Drug Targets (2008) 7:468–81.10.2174/187152708786927859
140
JaneroDRMakriyannisA. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs (2009) 14:43–65.10.1517/14728210902736568
141
McLaughlinPJ. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity. Behav Pharmacol (2012) 23:537–50.10.1097/FBP.0b013e3283566a8c
142
KangasBDDelatteMSVemuriVKThakurGANikasSPSubramanianKVet alCannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther (2013) 344:561–7.10.1124/jpet.112.201962
Summary
Keywords
cannabinoid system, nicotine, addiction, endogenous cannabinoids
Citation
Gamaleddin IH, Trigo JM, Gueye AB, Zvonok A, Makriyannis A, Goldberg SR and Le Foll B (2015) Role of the Endogenous Cannabinoid System in Nicotine Addiction: Novel Insights. Front. Psychiatry 6:41. doi: 10.3389/fpsyt.2015.00041
Received
15 September 2014
Accepted
06 March 2015
Published
25 March 2015
Volume
6 - 2015
Edited by
Steven R. Laviolette, University of Western Ontario, Canada
Reviewed by
Marco Pistis, University of Cagliari, Italy; Justine Renard, University of Western Ontario, Canada
Copyright
© 2015 Gamaleddin, Trigo, Gueye, Zvonok, Makriyannis, Goldberg and Le Foll.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bernard Le Foll, Translational Addiction Research Laboratory, Centre for Addiction and Mental Health (CAMH), University of Toronto, 33 Russell Street, Toronto, ON M5S 2S1, Canada e-mail: bernard.lefoll@camh.ca
†Islam Hany Gamaleddin and Jose M. Trigo have contributed equally to this work.
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Psychiatry.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.